122 related articles for article (PubMed ID: 1972825)
1. Immunohistochemical analysis of pulmonary and pleural neoplasms with monoclonal antibodies B72.3 and CSLEX-1.
Koukoulis GK; Radosevich JA; Warren WH; Rosen ST; Gould VE
Virchows Arch B Cell Pathol Incl Mol Pathol; 1990; 58(6):427-33. PubMed ID: 1972825
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical evaluation of ras oncogene expression in pulmonary and pleural neoplasms.
Lee I; Gould VE; Radosevich JA; Thor A; Ma YX; Schlom J; Rosen ST
Virchows Arch B Cell Pathol Incl Mol Pathol; 1987; 53(3):146-52. PubMed ID: 2888232
[TBL] [Abstract][Full Text] [Related]
3. Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma.
Ordóñez NG
Am J Surg Pathol; 1998 Oct; 22(10):1215-21. PubMed ID: 9777983
[TBL] [Abstract][Full Text] [Related]
4. Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma.
Brown RW; Clark GM; Tandon AK; Allred DC
Hum Pathol; 1993 Apr; 24(4):347-54. PubMed ID: 7684019
[TBL] [Abstract][Full Text] [Related]
5. The immunohistochemical diagnosis of mesothelioma. Differentiation of mesothelioma and lung adenocarcinoma.
Ordóñez NG
Am J Surg Pathol; 1989 Apr; 13(4):276-91. PubMed ID: 2648877
[TBL] [Abstract][Full Text] [Related]
6. Distinguishing malignant mesothelioma from pulmonary adenocarcinoma: an immuno-histochemical approach using a panel of monoclonal antibodies.
Tuttle SE; Lucas JG; Bucci DM; Schlom J; Primus J
J Surg Oncol; 1990 Oct; 45(2):72-8. PubMed ID: 2214794
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical evaluation of seven monoclonal antibodies for differentiation of pleural mesothelioma from lung adenocarcinoma.
Wirth PR; Legier J; Wright GL
Cancer; 1991 Feb; 67(3):655-62. PubMed ID: 1702354
[TBL] [Abstract][Full Text] [Related]
8. Value of the MOC-31 monoclonal antibody in differentiating epithelial pleural mesothelioma from lung adenocarcinoma.
Ordóñez NG
Hum Pathol; 1998 Feb; 29(2):166-9. PubMed ID: 9490276
[TBL] [Abstract][Full Text] [Related]
9. The value of antibodies 44-3A6, SM3, HBME-1, and thrombomodulin in differentiating epithelial pleural mesothelioma from lung adenocarcinoma: a comparative study with other commonly used antibodies.
Ordóñez NG
Am J Surg Pathol; 1997 Dec; 21(12):1399-408. PubMed ID: 9414183
[TBL] [Abstract][Full Text] [Related]
10. Differentiation of adenocarcinoma of the lung from mesothelioma. Periodic acid-Schiff, monoclonal antibodies B72.3, and Leu M1.
Warnock ML; Stoloff A; Thor A
Am J Pathol; 1988 Oct; 133(1):30-8. PubMed ID: 2845790
[TBL] [Abstract][Full Text] [Related]
11. Phenotypic characterization of lung cancers in fine needle aspiration biopsies using monoclonal antibody B72.3.
Johnston WW; Szpak CA; Thor A; Schlom J
Cancer Res; 1986 Dec; 46(12 Pt 1):6462-70. PubMed ID: 3022920
[TBL] [Abstract][Full Text] [Related]
12. Complementary value of five carcinoma markers for the diagnosis of malignant mesothelioma, adenocarcinoma metastasis, and reactive mesothelium in serous effusions.
Delahaye M; van der Ham F; van der Kwast TH
Diagn Cytopathol; 1997 Aug; 17(2):115-20. PubMed ID: 9258618
[TBL] [Abstract][Full Text] [Related]
13. Neuroendocrine differentiation in endocrine and nonendocrine lung carcinomas.
Linnoila RI; Mulshine JL; Steinberg SM; Funa K; Matthews MJ; Cotelingam JD; Gazdar AF
Am J Clin Pathol; 1988 Dec; 90(6):641-52. PubMed ID: 2848408
[TBL] [Abstract][Full Text] [Related]
14. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K
Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
[TBL] [Abstract][Full Text] [Related]
15. Expression of thrombomodulin, calretinin, cytokeratin 5/6, D2-40 and WT-1 in a series of primary carcinomas of the lung: an immunohistochemical study in comparison with epithelioid pleural mesothelioma.
Comin CE; Novelli L; Cavazza A; Rotellini M; Cianchi F; Messerini L
Tumori; 2014; 100(5):559-67. PubMed ID: 25343553
[TBL] [Abstract][Full Text] [Related]
16. Synchronous diffuse malignant mesothelioma and carcinomas in asbestos-exposed individuals.
Attanoos RL; Thomas DH; Gibbs AR
Histopathology; 2003 Oct; 43(4):387-92. PubMed ID: 14511258
[TBL] [Abstract][Full Text] [Related]
17. Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types: an immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura.
Miettinen M; Sarlomo-Rikala M
Am J Surg Pathol; 2003 Feb; 27(2):150-8. PubMed ID: 12548160
[TBL] [Abstract][Full Text] [Related]
18. The value of cytokeratins 20 and 7 in discriminating metastatic adenocarcinomas from pleural mesotheliomas.
Tot T
Cancer; 2001 Nov; 92(10):2727-32. PubMed ID: 11745209
[TBL] [Abstract][Full Text] [Related]
19. Value of the Ber-EP4 antibody in differentiating epithelial pleural mesothelioma from adenocarcinoma. The M.D. Anderson experience and a critical review of the literature.
Ordóñez NG
Am J Clin Pathol; 1998 Jan; 109(1):85-9. PubMed ID: 9426522
[TBL] [Abstract][Full Text] [Related]
20. Detection of epithelial- and neural type of intermediate filament proteins in human lung tumors.
Ramaekers F; Broers J; Rot MK; Oostendorp T; Wagenaar S; Vooijs P
Acta Histochem Suppl; 1987; 34():45-56. PubMed ID: 3033739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
